Monographie - Irinotecan

Última actualização :
19/11/2024

Irinotecan

estrutura química

Nomes comerciais nos diversos países

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Asinib	México
Axinotecan	Alemanha
Campto	Africa do sul, Austria, Bélgica, Croácia, Dinamarca, Emirados Árabes Unidos, Espanha, Finlandia, França, Gran-bretanha, Grècia, Hungria, Índia, Irã, Irlanda, Itália, Japón, Luxemburgo, Malásia, Marrocos, Noruega, Países Baixos, Polonia, Portugal, Suècia, Suicia, Tailandia, Tunísia, Turquia
Camptosar	Brasil, Canadá, Estados Unidos de América
Irinoliquid	Austria
Irnocam	Brasil

Bibliografía : Irinotecan

	tipo	publicação
1423	jornal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1617	jornal	Li WY, Koda RT. Stability of irinotecan hydrochloride in aqueous solutions. Am J Health-Syst Pharm 2002 ; 59: 539-544.
1662	jornal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1918	jornal	Dodds HM, Craik DJ, Rivory LP. Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition. J Pharm Sci 1997 ; 86, 12: 1410-1416.
1920	jornal	Akimoto K, Kaway A, Ohya K et al. Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution. Drug Stability 1996 ; 1: 118-122.
1921	jornal	Akimoto K, Kawai A, Ohya K. Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution. Drug Stability 1996 ; 1; 141-146.
1953	jornal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976	jornal	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.
2027	jornal	Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222.
2143	jornal	Dodds HM, Robert J, Rivory LP. The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry. J Pharm Biomed Anal 1998 ; 17: 785-792.
2168	jornal	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2241	jornal	Thiesen J, Krämer I. Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags. J Oncol Pharm Practice 2000 ; 6, 3: 115-121.
2340	jornal	Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222.
2671	jornal	Kaiser J, Thiesen J, Krämer I. Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization. J Oncol Pharm Practice 2010 ; 16: 53-61.
3129	Laboratório	Irinotécan (Campto®) – Résumé des caractéristiques du produits Pfizer 2008
3369	Laboratório	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3670	jornal	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3873	jornal	Tan X, Hu J. Incompatibility between irinotecan and fluorouracil injections Am J Health-Syst Pharm 2016 ; 73:755.

Mentions Légales